MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Risk Capital_Angel, Venture (VC), Strategic Corporate( CVC), Private Equity (PE), Mergers and Acquisition (M&A) (Trends)
2022: Medtech's top 10 money raisers of 2021
Freenome
Organization & Developments: Freenome
Parents
Freenome
Children
* The company aims to reinvent disease management through systematized early detection and intervention.
* The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome.
*Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages.
2021: Freenome, high-profile liquid biopsy company, quietly replaces its CEO
2024: Early cancer-detection test maker Freenome to cut 20% of jobs
2024: Freenome Raises $254M for Multiomic-Based Early Cancer Detection
2026: FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
Jumps
*Key People: Freenome
Finance & Acquisitions: Freenome